You will be redirected to our submission process. Ocular immunology investigates the complex interplay between molecular mediators and immune cells responsible for maintaining ocular immune privilege, ...

New phase 3 data showed that patients with primary immune thrombocytopenia saw improved disease control when ianalumab was added to Promacta (eltrombopag) treatment compared to Promacta alone. Data ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

ITP is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting.

Dietary iron deficiency in mice alters lung T cell activation during influenza infection and leads to memory T cells that are ...

In a confirmatory model adjusted for baseline illness severity, the precision immunotherapy approach was associated with ...

In a recent preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody ...

Enhertu (trastuzumab Deruxtecan [T-DXd]) treated patients continue to be eligible for enrollment in FLAMINGO-01. The Company believes that GLSI-100 will synergize with any trastuzumab based treatment ...